Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Maetzler, Walter ^a,b   Apel, Anja ^a,b   Langkamp, Markus ^c   Deuschle, Christian ^a,b   Dilger, Sarah Selina ^a,b   Stirnkorb, Johannes Georg ^a,b   Schulte, Claudia ^a,b   Schleicher, Erwin ^d   Gasser, Thomas ^a,b   Berg, Daniela ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c Mediagnost   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AUTOANTIBODY; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN S100B; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HEAT SHOCK PROTEIN; HLA DR ANTIGEN; MOLECULAR CHAPERONE GRP78; PROTEIN SERINE THREONINE KINASE; SNCA PROTEIN, HUMAN; STK39 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; NONPARAMETRIC TEST;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; AUTOANTIBODIES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOGEN SYNTHASE KINASE 3; HEAT-SHOCK PROTEINS; HLA-DR ALPHA-CHAINS; HUMANS; MYELIN BASIC PROTEIN; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; STATISTICS, NONPARAMETRIC;

EID: 84896793936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088604     Document Type: Article

References (40)

1. Neff F, Wei X, Nolker C, Bacher M, Du Y, et al. (2008) Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 7: 501-507.
2. Kwekkeboom J (2012) Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies. Adv Exp Med Biol 750: 133-144.
3. Bach JP, Dodel R (2012) Naturally occurring autoantibodies against beta-Amyloid. Adv Exp Med Biol 750: 91-99.
4. Maetzler W, Langkamp M, Lerche S, Godau J, Brockmann K, et al. (2012) Lowered Serum Amyloid-beta1-42 Autoantibodies in Individuals with Lifetime Depression. J Alzheimers Dis 32: 95-100.
5. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, et al. (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A 106: 12145-12150.
6. Du J, Cho PY, Yang DT, Murphy RM (2012) Identification of beta-amyloid-binding sites on transthyretin. Protein Eng Des Sel 25: 337-345.
7. Storace D, Cammarata S, Borghi R, Sanguineti R, Giliberto L, et al. (2010) Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Arch Neurol 67: 867-872.
8. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, et al. (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12: 233-243.
9. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, et al. (2011) alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 6: e18513.
10. Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, et al. (2011) Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol 233: 221-227.
11. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, et al. (2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101: 749-756. (Pubitemid 46633311)
12. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, et al. (2013) Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80: 169-175.
13. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, et al. (2011) Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 26: 171-179.
14. Wilhelm KR, Yanamandra K, Gruden MA, Zamotin V, Malisauskas M, et al. (2007) Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. Eur J Neurol 14: 327-334. (Pubitemid 46384873)
15. Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, et al. (2012) S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 135: 3336-3347.
16. Koehler NK, Stransky E, Shing M, Gaertner S, Meyer M, et al. (2013) Altered Serum IgG Levels to alpha-Synuclein in Dementia with Lewy Bodies and Alzheimer's Disease. PLoS One 8: e64649.
17. Rubinsztein DC, Easton DF (1999) Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement Geriatr Cogn Disord 10: 199-209. (Pubitemid 29224496)
18. Seripa D, Bizzarro A, Panza F, Acciarri A, Pellegrini F, et al. (2011) The APOE gene locus in frontotemporal dementia and primary progressive aphasia. Arch Neurol 68: 622-628.
19. Inkster B, Hichols T, Saemann P, Auer D, Holsboer F, et al. (2009) Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatr 66: 721-728.
20. Izzo G, Forlenza O, Santos B, Bertolucci P, Ojopi E, et al. (2013) Single-nucleotide polymorphisms of GSK3B, GAB2 und SORL1 in late-onset Alzheimer's Disease: interactions with the APOE genotype. Clinics (Sao Paulo) 68: 277-280.
21. Guo Y, Deng X, Zheng W, Xu H, Song Z, et al. (2011) HLA rs3129882 variant in Chinese Han patients with late-onset sporadic Parkinson disease. Neurosci Lett 501: 185-187.
22. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42: 781-785.
23. Kakiuchi C, Ishiwata M, Nanko S, Kunugi H, Minabe Y, et al. (2005) Functional polymorphisms of HSPA5: possible association with bipolar disorder. Biochem Biophys Res Commun 336: 1136-1143. (Pubitemid 41383440)
24. Zhu X, Chen MS, Tian LW, Li DP, Xu PL, et al. (2009) Single nucleotide polymorphism of rs430397 in the fifth intron of GRP78 gene and clinical relevance of primary hepatocellular carcinoma in Han Chinese: risk and prognosis. Int J Cancer 125: 1352-1357.
25. Pan F, Dong H, Ding H, Ye M, Liu W, et al. (2012) SNP rs356219 of the alpha-synuclein (SNCA) gene is associated with Parkinson's disease in a Chinese Han population. Parkinsonism Relat Disord 18: 632-634.
26. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, et al. (2008) Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 22: 1327-1334. (Pubitemid 351656774)
27. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, et al. (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67: 1350-1356.
28. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, et al. (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet 8: e1002548.
29. Chen LY, Zhao WH, Tian W, Guo J, Jiang F, et al. (2012) STK39 is an independent risk factor for male hypertension in Han Chinese. Int J Cardiol 154: 122-127.
30. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.
31. Hobert MA, Niebler R, Meyer SI, Brockmann K, Becker C, et al. (2011) Poor trail making test performance is directly associated with altered dual task prioritization in the elderly-baseline results from the TREND study. PLoS One 6: e27831.
32. Heinzel S, Metzger FG, Ehlis AC, Korell R, Alboji A, et al. (2013) Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. Neurobiol Aging 34: 439-450.
33. Maetzler W, Schmid SP, Wurster I, Liepelt I, Gaenslen A, et al. (2011) Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 26: 176-181.
34. Langkamp M, Hornig SC, Hornig JB, Kirschner M, Pridzun L, et al. (2009) Detection of myelin autoantibodies: evaluation of an assay system for diagnosis of multiple sclerosis in differentiation from other central nervous system diseases. Clin Chem Lab Med 47: 1395-1400.
35. Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA (2010) Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods 187: 263-269.
36. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ (1998) Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 785: 195-206. (Pubitemid 28179382)
37. Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, et al. (2010) Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 227: 167-174.
38. Notkins AL (2004) Polyreactivity of antibody molecules. Trends Immunol 25: 174-179.
39. Fetissov SO (2011) Neuropeptide autoantibodies assay. Methods Mol Biol 789: 295-302.
40. Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, et al. (2011) Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 144: 132-142.